Browsing Tag
biotechnology
73 posts
Could oral elraglusib emerge as a combination backbone for RAS-targeted cancer therapies?
Actuate Therapeutics, Inc. is advancing oral elraglusib to target resistance biology in cancer. Discover what this means for oncology markets.
Can in vivo CAR T therapies expand access beyond specialized treatment centers
Explore how CPTx’s in vivo CAR T strategy could lower costs, simplify delivery, and expand access beyond specialized cancer treatment centers.
Why BIOX-101 might succeed where decades of stroke research have struggled
Can BIOX-101 reshape stroke treatment timelines? Discover how Bioxodes SA’s strategy could accelerate approvals and change neurovascular care.
Why AACR 2026 data on FT839 matters for hematologic cancer and autoimmune markets
Find out how Fate Therapeutics, Inc.’s FT839 could reshape CAR T economics and expand into autoimmune disease markets. Read the full analysis.
Why industry observers are watching Tenvie Therapeutics’ TNV262 biomarker readout in 2026
Tenvie Therapeutics’ TNV262 readout in 2026 could reshape obesity and cardiometabolic drug development. Read why markets are watching closely.
Can Ocugen, Inc. disrupt chronic eye injections with a single gene therapy procedure? (NASDAQ: OCGN)
Ocugen, Inc. reports Phase 2 gene therapy results that could reshape retinal treatment economics. Discover what this means for investors and competitors.
Aelis Farma’s AEF0217 enters critical Phase 2B trial—can it become the first drug for Down syndrome cognition?
Aelis Farma launches Phase 2B trial for AEF0217 in Down syndrome—could this CB1-targeting drug finally deliver a breakthrough? Read more.
Curi Bio and Battelle partner to scale human-relevant neuromuscular testing platforms as FDA shifts toward animal-free drug development
Curi Bio and Battelle announce strategic partnership to commercialize neuromuscular junction testing technology, positioning for regulatory shift toward human-relevant drug development methods.
Why Hims & Hers Health’s decision to offer Grail’s Galleri test looks riskier after the U.K. NHS trial miss
Grail’s Galleri cancer test missed a major U.K. NHS trial goal just as Hims & Hers Health began offering it. Find out what this means for investors and screening strategy.
Why NervGen Pharma Corp’s Chief Financial Officer retirement matters more than it appears
NervGen Pharma Corp announces its Chief Financial Officer’s planned retirement. Find out what the leadership change signals for capital strategy and investors.